RT Journal Article
SR Electronic
T1 Anti-Tumor Necrosis Factor Therapies in Immune-Mediated Rheumatic Diseases. Other Observations from the Clinic
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 53
OP 62
DO 10.3899/jrheum.091465
VO 85
A1 ANTHONY S. RUSSELL
A1 JAMES T. ROSENBAUM
YR 2010
UL http://www.jrheum.org/content/85/53.abstract
AB To date, over 2 million patients worldwide have been treated with anti-tumor necrosis factor (TNF) therapies, dramatically improving the treatment outcomes of immune-mediated inflammatory diseases (IMID). Observations from clinicians have identified some curious disconnects between clinical and radiographic outcomes, and the paradoxical occurrence of anti-TNF therapy-induced IMID such as psoriasis or reactivation of uveitis and Crohn’s disease. These observations point to the need for a better understanding of the mechanisms underlying the ability of anti-TNF therapies to reduce inflammation and how this is linked to the pathogenesis of IMID.